| pubmed-article:16688094 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0019693 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0205466 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0034107 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C1999177 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0206034 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C1512900 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:16688094 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:16688094 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16688094 | pubmed:dateCreated | 2006-6-8 | lld:pubmed |
| pubmed-article:16688094 | pubmed:abstractText | Structured treatment interruptions (STIs) have been postulated to improve virologic control in primary HIV infection (PHI) by stimulating HIV-specific T-lymphocyte immunity. The addition of hydroxyurea (HU) may reduce viral production from activated CD4 cells. | lld:pubmed |
| pubmed-article:16688094 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16688094 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16688094 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16688094 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16688094 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16688094 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16688094 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16688094 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:16688094 | pubmed:issn | 1525-4135 | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:LawMatthewM | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:KaldorJohn... | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:CooperDavid... | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:CarrAndrewA | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:KelleherAntho... | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:ZaundersJohn... | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:GreyPatP | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:SmithDon EDE | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:PetoumenosKat... | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:McFarlaneRobe... | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:QuanDickD | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:BlochMark TMT | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:IrvineKathyK | lld:pubmed |
| pubmed-article:16688094 | pubmed:author | pubmed-author:FinlaysonRobe... | lld:pubmed |
| pubmed-article:16688094 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16688094 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:16688094 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16688094 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16688094 | pubmed:pagination | 192-202 | lld:pubmed |
| pubmed-article:16688094 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:meshHeading | pubmed-meshheading:16688094... | lld:pubmed |
| pubmed-article:16688094 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16688094 | pubmed:articleTitle | The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). | lld:pubmed |
| pubmed-article:16688094 | pubmed:affiliation | Holdsworth House Medical Practice, Sydney, New South Wales, Australia. | lld:pubmed |
| pubmed-article:16688094 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16688094 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:16688094 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16688094 | lld:pubmed |
